Skip to main content
. Author manuscript; available in PMC: 2019 Mar 25.
Published in final edited form as: Cancer Res. 2018 Dec 12;79(6):1214–1225. doi: 10.1158/0008-5472.CAN-18-1127

Figure 1. Overview of next-generation sequencing and T cell analyses.

Figure 1.

We used serial blood samples collected at baseline, early after treatment initiation and at additional timepoints during immune checkpoint blockade to determine ctDNA and TCR repertoire dynamics. ctDNA trends were evaluated by TEC-Seq and the evolving TCR repertoire was assessed by TCR next generation sequencing. Dynamic changes in ctDNA and TCR clonotypic expansions were used to identify molecular response patterns and compared to RECIST 1.1 tumor burden evaluations. T0–T4 denote serial timepoints from the time of treatment initiation (T0), to the time of molecular response (T1), radiologic response (T2), molecular resistance (T3) and radiologic progression (T4).